Drug Profile
Research programme: Zika virus antibody therapeutics - Caerus Discovery/George Mason University
Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Caerus Discovery; George Mason University
- Class Antibodies; Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Zika virus infection
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for research development in Zika-virus-infection in USA (Parenteral)
- 15 Feb 2017 Caerus Discovery and George Mason University agree to develop Zika virus antibody therapeutics
- 15 Feb 2017 Early research in Zika virus infection in USA (Parenteral)